RESUMEN
INTRODUCTION: Finding novel medical treatment for Peyronie's disease (PD) has suffered from similar limitations and difficulties as other fibrotic diseases.Areas covered: Underlying fibrosis, there is a vastly complex intertwining of several pathways. Focusing on a single target during antifibrotic drug development has not led to the development of many efficacious drugs, especially in PD. Inhibiting one cog in this large machinery usually leads to activation of compensatory mechanisms.Expert opinion: Novel strategies in drug discovery such as phenotypical drug screening and gene expression profiling technologies could provide a solution for this impasse.
Asunto(s)
Desarrollo de Medicamentos/métodos , Descubrimiento de Drogas/métodos , Induración Peniana/tratamiento farmacológico , Perfilación de la Expresión Génica/métodos , Humanos , Masculino , Induración Peniana/genética , Induración Peniana/fisiopatologíaRESUMEN
BACKGROUND: Electrosurgery makes dissection with simultaneous haemostasis possible. The produced heat can cause injury to the surrounding tissue. The PEAK PlasmaBlade™(PPB) is a new electrosurgery device which may overcome this by having the ability to operate on a lower temperature, therefore reducing collateral thermal damage. METHOD: A single-centre, double-blinded, randomised controlled trial (RCT) was conducted which included 108 abdominal-based free-flap breast reconstruction patients who had their flap raise performed using either the PPB (nâ¯=â¯56) or the conventional diathermy (nâ¯=â¯52). Data were collected during their in-patient stay and out-patient appointments. The primary outcome value was the number of days the abdominal drains were required. RESULTS: Baseline characteristics were similar between the groups, except a significantly lower flap weight in the PPB group. The median number of days the drains were required did not differ significantly (pâ¯=â¯0.48; 6.0 days for the diathermy and 5.0 days for the PPB). The total drain output (pâ¯=â¯0.68), the inflammatory cytokine in the drain fluid (p>0.054) and complications (p>0.24) did not differ significantly between the two groups. At the 2-week follow-up appointment, there was a trend towards less abdominal seromas on abdominal ultrasound (pâ¯=â¯0.09) in the PPB group which were significantly smaller (pâ¯=â¯0.04). CONCLUSION: The use of the PPB did not result in a significant reduction of drain requirement, total drain output or inflammatory cytokines but did reduce the size of seroma collections at the 2-week follow-up appointment. Therefore, the use of the PPB device could reduce early seroma formation after drain removal.
Asunto(s)
Abdomen/cirugía , Neoplasias de la Mama/cirugía , Diatermia/métodos , Colgajos Tisulares Libres/trasplante , Mamoplastia/métodos , Sitio Donante de Trasplante/cirugía , Adulto , Citocinas/metabolismo , Método Doble Ciego , Drenaje , Inglaterra , Femenino , Humanos , Persona de Mediana Edad , Complicaciones Posoperatorias/prevención & control , Seroma/prevención & controlRESUMEN
Previous studies have demonstrated mixed inhibitory and facilitatory effects of 5-hydroxytryptamine-4 (5-HT(4)) receptor agonists on electrical field stimulation (EFS)-induced responses in human isolated colon. Here we report three types of responses to EFS in human isolated colon circular muscle: monophasic cholinergic contraction during EFS, biphasic response (nitrergic relaxation during EFS followed by cholinergic contraction after termination of EFS) and triphasic response (cholinergic contraction followed by nitrergic relaxation during EFS and a tachykininergic contraction after EFS). The effects of two 5-HT(4) receptor agonists, prucalopride and tegaserod were then investigated on monophasic responses only. Each compound inhibited contractions during EFS in a concentration-dependent manner. In the presence of N(omega)-nitro-l-arginine methyl ester (l-NAME) however, prucalopride and tegaserod enhanced the contractions in a concentration-dependent manner. In strips where the tone was elevated with substance-P and treated with scopolamine, EFS-induced relaxations were enhanced by the two agonists. The above observed effects by the two agonists were abolished by 5-HT(4) receptor antagonist SB-204070. The two agonists did not alter the tone raised by substance-P in the presence of scopolamine and l-NAME and did not affect carbachol-induced contractions in the presence of tetrodotoxin. These results suggest that in the circular muscle of human colon, 5-HT(4) receptor agonists simultaneously facilitate the activity of neurones which release the inhibitory and excitatory neurotransmitters, nitric oxide and acetylcholine respectively.
Asunto(s)
Acetilcolina/metabolismo , Colon/efectos de los fármacos , Colon/fisiología , Músculo Liso/efectos de los fármacos , Óxido Nítrico/metabolismo , Agonistas del Receptor de Serotonina 5-HT4 , Adulto , Anciano , Anciano de 80 o más Años , Benzofuranos/farmacología , Relación Dosis-Respuesta a Droga , Estimulación Eléctrica , Inhibidores Enzimáticos/farmacología , Femenino , Humanos , Indoles/farmacología , Masculino , Persona de Mediana Edad , Antagonistas Muscarínicos/farmacología , Contracción Muscular/efectos de los fármacos , Contracción Muscular/fisiología , Relajación Muscular/efectos de los fármacos , Relajación Muscular/fisiología , Músculo Liso/metabolismo , NG-Nitroarginina Metil Éster/farmacología , Antagonistas del Receptor de Neuroquinina-1 , Neurotransmisores/farmacología , Técnicas de Cultivo de Órganos , Receptores de Neuroquinina-2/antagonistas & inhibidores , Receptores de Neuroquinina-3/antagonistas & inhibidores , Escopolamina/farmacología , Sustancia P/farmacologíaRESUMEN
The effects of hypoxia (pO2: 50 mmHg), acidosis (pH: 6.9) or glucopenia (absence of glucose) in vitro on the tone of the rabbit corpus cavernosum were investigated. The recovery of smooth muscle contractility following exposure to these conditions was also assessed. Hypoxia, acidosis or glucopenia alone or in combination showed a sustained reduction in the tone. Reperfusion of tissue strips showed complete recovery of smooth muscle tone for all conditions except when hypoxia and glucopenia were combined or when hypoxia, glucopenia and acidosis were used in combination. Incomplete recovery of tone was associated with a significant reduction in tissue ATP concentrations and an increase in the number of TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling)-positive nuclei. This indicates that following reversal of hypoxia, acidosis and glucopenia, failure of conventional alpha-adrenergic agonists to produce tumescence in low flow priapism is associated with irreversible smooth muscle cell dysfunction, which is linked to ATP reduction and smooth muscle cell death.
Asunto(s)
Músculo Liso Vascular/fisiopatología , Pene/irrigación sanguínea , Pene/fisiología , Priapismo/fisiopatología , Acidosis/metabolismo , Adenosina Trifosfato/metabolismo , Animales , Técnica del Anticuerpo Fluorescente , Glucosa/deficiencia , Hipoxia/metabolismo , Inmunohistoquímica , Técnicas In Vitro , Masculino , Tono Muscular/efectos de los fármacos , Óxido Nítrico/metabolismo , Fenilefrina/farmacología , Conejos , Vasoconstrictores/farmacologíaRESUMEN
Aberrations in nitrergic neurotransmission, due to a decrease in neuronal nitric oxide (NO) synthase (nNOS) protein, play an important role in the pathogenesis of autonomic neuropathy in diabetes. Until recently the mechanism of the decrease in nNOS protein content in nitrergic nerves during diabetes was debated. Two different views were prevailing, one attributing the nNOS decrease to nitrergic nerve degeneration, the other to an alteration in nNOS expression. Our recent study in which we showed that nitrergic nerves undergo a degenerative process in two phases might bring a solution to this debate. Our model suggests that, in the early stages of diabetes, nNOS expression is decreased in the nitrergic axons while nNOS levels are unaffected in the cell bodies, most probably due to a defect in axonal transport. This decrease is reversible with insulin treatment. As the diabetes progresses, nNOS starts to accumulate in the cell bodies since it cannot be transported down to the axons. Increased nNOS protein and NO production coincide with accumulation of advanced glycation endproducts (AGEs) in the blood and tissues. Synergistic action of AGEs and endogenous NO leads to increased oxidative stress within the cell bodies, resulting in apoptosis. This degenerative phase of nitrergic neuropathy is not reversible with insulin treatment. This suggests a point of no return for autonomic nerves after which the degenerative changes become irreversible. Future therapeutic approaches could target the defective axonal transport and prevention of AGEs accumulation before this point of no return. In the later stages, reduction of AGEs, replenishment of lost nitrergic neurons and restoration of function are putative therapeutic targets.
Asunto(s)
Neuropatías Diabéticas/metabolismo , Neurotransmisores/metabolismo , Neuronas Nitrérgicas/metabolismo , Óxido Nítrico/metabolismo , Animales , Apoptosis/efectos de los fármacos , Neuropatías Diabéticas/enzimología , Neuropatías Diabéticas/patología , Humanos , Hipoglucemiantes/farmacología , Degeneración Nerviosa/metabolismo , Degeneración Nerviosa/patología , Neuronas Nitrérgicas/enzimología , Neuronas Nitrérgicas/patología , Óxido Nítrico Sintasa/metabolismo , Óxido Nítrico Sintasa de Tipo IRESUMEN
1. Electrical field stimulation (EFS) of the superfused lower oesophageal sphincter from opossum (Monodelphis domestica) elicited biphasic responses. The first phase (relaxation) was strictly dependent on the duration of the EFS. The second phase (contraction) started following termination of the EFS (< or = 15 Hz). EFS at frequencies above 15 Hz led only to contraction, which started immediately upon initiation of the stimulation. 2. In the presence of NG-nitro-L-arginine (L-NOARG; 0.1-300 microM), the relaxation phase was abolished and the contractile response started with the initiation of EFS (at all frequencies) and was greater in magnitude. The contractile response to EFS was completely blocked with scopolamine (10 microM). 3. Exogenous acetylcholine (1-100 microM) elicited concentration-dependent contractions of the sphincter in the presence of botulinum toxin. These contractions were abolished when EFS was applied during administration of acetylcholine. This inhibitory effect of EFS was completely reversed when the tissue was treated with L-NOARG (100 microM). 4. These results suggest that the cholinergic response in the opossum lower oesophageal sphincter is under nitrergic control.
Asunto(s)
Unión Esofagogástrica/efectos de los fármacos , Óxido Nítrico/fisiología , Receptores Colinérgicos/efectos de los fármacos , Acetilcolina/farmacología , Animales , Toxinas Botulínicas/farmacología , Estimulación Eléctrica , Unión Esofagogástrica/fisiología , Técnicas In Vitro , Masculino , Contracción Muscular/efectos de los fármacos , Relajación Muscular/efectos de los fármacos , Nitroarginina/farmacología , Zarigüeyas , Receptores Colinérgicos/fisiologíaRESUMEN
The corpus cavernosum is the erectile tissue in the penis and clitoris. Although nitrergic neurotransmission has been characterized in detail in the penile corpus cavernosum, functional studies on the inhibitory non-adrenergic non-cholinergic (NANC) transmission in the clitoral corpus cavernosum have been lacking. Here we demonstrate that electrical field stimulation (EFS) induces NANC relaxation responses in the clitoral corpus cavernosum of the rabbit. These responses were inhibited by NG-nitro-L-arginine methylester (L-NAME), 1H-[1,2,4]oxadiazolo[4,3,-a]quinoxalin-1-one (ODQ) or tetrodotoxin. The inhibitory effect of L-NAME was partially reversed by L-arginine but not by D-arginine. EFS-induced relaxations were enhanced by an inhibitor of type V cyclic GMP phosphodiesterase, zaprinast. These results suggest that nitrergic neurotransmission is responsible for the NANC relaxation responses in the clitoral corpus cavernosum of the rabbit.
Asunto(s)
Clítoris/fisiología , Óxido Nítrico/fisiología , Pene/fisiología , Transmisión Sináptica/fisiología , Animales , Arginina/farmacología , Clítoris/efectos de los fármacos , Clítoris/inervación , Relación Dosis-Respuesta a Droga , Estimulación Eléctrica , Inhibidores Enzimáticos/farmacología , Femenino , Guanilato Ciclasa/antagonistas & inhibidores , Técnicas In Vitro , Masculino , Relajación Muscular/efectos de los fármacos , NG-Nitroarginina Metil Éster/farmacología , Oxadiazoles/farmacología , Erección Peniana/efectos de los fármacos , Erección Peniana/fisiología , Pene/efectos de los fármacos , Pene/inervación , Purinonas/farmacología , Quinoxalinas/farmacología , Conejos , Transmisión Sináptica/efectos de los fármacos , Tetrodotoxina/farmacologíaRESUMEN
1. Isolated preparations of rabbit anococcygeus muscle were exposed to electrical field stimulation (EFS; 50V, 0.3 ms duration, 0.08-40 Hz) for periods of 1-60 s (short-term EFS) or 10 min-2 h (long-term EFS). 2. Both short- and long-term EFS caused a contractile response which was enhanced by the nitric oxide (NO) synthase inhibitor, NG-nitro-L-arginine (L-NOARG), showing that it is modulated by endogenous NO. 3. In preparations treated with scopolamine and guanethidine and in which a constrictor tone was induced by histamine, both short- and long-term EFS resulted in relaxation of the tissue. 4. Such relaxations were reversed by tetrodotoxin (TTX), omega-conotoxin, inhibitors of NO synthase and the NO scavenger, oxyhaemoglobin, indicating that they are neuronal in origin and nitrergic in nature. 5. The relaxations to long-term EFS persisted for the duration of the stimulation and were associated with sustained release of oxidation products of NO (NOx). The EFS-induced release of NOx was decreased by N-iminoethyl-L-ornithine (L-NIO), an inhibitor of NO synthase, and by TTX. 6. Inhibitors of NO synthase, in addition, increased the basal tone of the tissue and reduced the basal output of NOx. The basal output of NOx was also reduced by TTX. 7. Long-term EFS which induces approximately 50% of the maximum relaxation could be enhanced by addition of L-, but not D-, arginine to the perfusion medium. 8. These data show that there is a continuous basal release of NO from nitrergic nerve terminals which maintains a relaxant tone in the rabbit anococcygeus muscle. 9. In addition, NO is released during short- and long-term EFS which further relaxes the preparation and modulates sympathetic transmission. Activation of the L-argimne: NO pathway for periods up to2 h does not exhaust nitrergic transmission in any appreciable way.
Asunto(s)
Músculos/metabolismo , Óxido Nítrico/metabolismo , Transmisión Sináptica , Adenosina Trifosfato/farmacología , Animales , Arginina/farmacología , Estimulación Eléctrica , Guanetidina/farmacología , Histamina/farmacología , Masculino , Relajación Muscular/fisiología , Músculos/efectos de los fármacos , Músculos/fisiología , Neurotoxinas/farmacología , Óxido Nítrico/fisiología , Nitroprusiato/farmacología , Conejos , Escopolamina/farmacología , Transmisión Sináptica/efectos de los fármacos , Transmisión Sináptica/fisiología , Péptido Intestinal Vasoactivo/farmacologíaRESUMEN
1. The actions of 1H-[1,2,4]oxadiazolo[4,3,-a]quinoxalin-1-one (ODQ), a specific inhibitor of the soluble guanylate cyclase (SGC), were investigated in the rabbit anococcygeus muscle. 2. ODQ (1 nM-1 microM) inhibited in a concentration-dependent manner the relaxations induced by electrical field stimulation (EFS; 50 V, 0.3 ms duration, 1 Hz, for 5 s, every 120 s). 3. ODQ (1 microM) also inhibited the relaxations elicited by EFS (50 V, 0.3 ms duration, 1, 2.5, 5, 10 Hz, for 5 s) and sodium nitroprusside (SNP; 1 microM) without affecting those induced by isoprenaline (1 microM), atrial natriuretic peptide (ANP; 100 nM) or an analogue of cyclic GMP (8-pCPT-cyclic GMP; 500 microM). 4. ODQ (1 microM) inhibited the elevations in the concentration of cyclic GMP induced by SNP or EFS, but not by ANP. ODQ did not affect the concentrations of cyclic AMP. 5. Nitrergic relaxation in this tissue appears, therefore, to be mediated via activation of SGC.
Asunto(s)
Inhibidores Enzimáticos/farmacología , Guanilato Ciclasa/antagonistas & inhibidores , Relajación Muscular/efectos de los fármacos , Óxido Nítrico/fisiología , Oxadiazoles/farmacología , Quinoxalinas/farmacología , Animales , GMP Cíclico/metabolismo , Estimulación Eléctrica , Técnicas In Vitro , Masculino , Relajación Muscular/fisiología , Músculo Liso/efectos de los fármacos , Músculo Liso/fisiología , Conejos , Solubilidad , Transmisión Sináptica/efectos de los fármacos , Transmisión Sináptica/fisiologíaRESUMEN
We have examined the effect of an inhibitor of Rho-kinase, (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl) cyclohexanecarboxamide dihydrochloride monohydrate (Y-27632), on the contractions elicited by noradrenergic nerve stimulation and by phenylephrine in the human and rabbit penile corpus cavernosum. In both tissues, after treatment with scopolamine (10 microM) and N(G)-nitro-L-arginine methyl ester (L-NAME; 300 microM), electrical field stimulation (EFS) elicited noradrenergic contractions. These contractions were inhibited by Y-27632 in a concentration-dependent manner. The compound caused concentration-dependent relaxation of phenylephrine-contracted tissues, which were treated with scopolamine (10 microM), guanethidine (10 microM) and L-NAME (300 microM). These results suggest that Rho-kinase is involved in noradrenergic contractile pathway in the cavernosal smooth muscle of the penis.
Asunto(s)
Amidas/farmacología , Contracción Muscular/efectos de los fármacos , Relajantes Musculares Centrales/farmacología , Pene/efectos de los fármacos , Piridinas/farmacología , Animales , Interacciones Farmacológicas , Estimulación Eléctrica , Inhibidores Enzimáticos/farmacología , Humanos , Técnicas In Vitro , Péptidos y Proteínas de Señalización Intracelular , Masculino , NG-Nitroarginina Metil Éster/farmacología , Pene/fisiología , Fenilefrina/farmacología , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Conejos , Transmisión Sináptica/efectos de los fármacos , Transmisión Sináptica/fisiología , Vasoconstrictores/farmacología , Quinasas Asociadas a rhoRESUMEN
1. In vitro and in vivo studies have demonstrated a dysfunctional nitrergic system in diabetes mellitus, thus explaining the origin of diabetic impotence. However, the mechanism of this nitrergic defect is not understood. 2. In the penises of streptozotocin (STZ)-induced diabetic rats, here, we show by immunohistochemistry that nitrergic nerves undergo selective degeneration since the noradrenergic nerves which have an anti-erectile function in the penis remained intact. 3. Nitrergic relaxation responses in vitro and erectile responses to cavernous nerve stimulation in vivo were attenuated in these animals, whereas noradrenergic responses were enhanced. 4. Activity and protein amount of neuronal nitric oxide synthase (nNOS) were also reduced in the penile tissue of diabetic rats. 5. We, thus, hypothesized that NO in the nitrergic nerves may be involved in the nitrergic nerve damage, since only the nerves which contain neuronal NO synthase underwent degeneration. 6. We administered an inhibitor of NO synthase, N(G)-nitro-L-arginine methyl ester (L-NAME), in the drinking water of rats for up to 12 weeks following the establishment of diabetes with STZ. 7. Here we demonstrate that this compound protected the nitrergic nerves from morphological and functional impairment. Our results show that selective nitrergic degeneration in diabetes is NO-dependent and suggest that inhibition of NO synthase is neuroprotective in this condition.
Asunto(s)
Diabetes Mellitus Experimental/metabolismo , Disfunción Eréctil/metabolismo , Degeneración Nerviosa/metabolismo , Óxido Nítrico Sintasa/metabolismo , Erección Peniana/fisiología , Pene/metabolismo , Animales , Diabetes Mellitus Experimental/complicaciones , Inhibidores Enzimáticos/farmacología , Disfunción Eréctil/etiología , Masculino , NG-Nitroarginina Metil Éster/farmacología , Degeneración Nerviosa/etiología , Óxido Nítrico Sintasa/efectos de los fármacos , Óxido Nítrico Sintasa de Tipo I , Óxido Nítrico Sintasa de Tipo III , Erección Peniana/efectos de los fármacos , Pene/efectos de los fármacos , Ratas , Ratas WistarRESUMEN
The endothelium-dependent relaxation in response to acetylcholine was significantly less in pulmonary artery strips from chickens fed 5% cholesterol for 4 weeks than in strips from animals fed an 'ordinary' diet. No relaxation was observed in the strips from either group when the endothelium was disrupted or the strips were pretreated with hydroquinone. These results indicate that the relaxing effect of acetylcholine is endothelium-dependent and that hypercholesterolemia leads to an impairment of the endothelium-mediated relaxation response of the pulmonary artery strips to acetylcholine.
Asunto(s)
Acetilcolina/farmacología , Colesterol en la Dieta/farmacología , Vasodilatación/efectos de los fármacos , Animales , Arteriosclerosis/etiología , Pollos , Endotelio/efectos de los fármacos , Endotelio/fisiología , Hipercolesterolemia/fisiopatología , Técnicas In Vitro , Masculino , Arteria Pulmonar/efectos de los fármacos , Arteria Pulmonar/fisiologíaRESUMEN
Although the presence of neuronal nitric oxide synthase (nNOS) has been demonstrated in human clitoral corpus cavernosum, functional evidence for the nitrergic neurotransmission as a nonadrenergic noncholinergic (NANC) transmitter has been limited to animal studies. Here we show that electrical field stimulation elicited reproducible NANC relaxation responses in a clitoral corpus cavernosum, obtained from a 38-y-old woman undergoing clitoral reduction surgery. These relaxation responses were abolished by an inhibitor of NO synthase or tetrodotoxin proving that they were nitrergic in nature and neuronal in origin. Large and small calibre nitrergic nerves were demonstrated with immunohistochemistry using nNOS antibody, which were also immunostained with cholinergic nerve markers. nNOS expression was confirmed using Western blotting. This is the first report to show that NO produced by nNOS within the cholinergic-nitrergic nerves is responsible for the NANC relaxation responses in a human clitoral corpus cavernosum.
Asunto(s)
Clítoris/inervación , Óxido Nítrico/fisiología , Transmisión Sináptica/fisiología , Adulto , Western Blotting , Clítoris/enzimología , Clítoris/cirugía , Estimulación Eléctrica , Femenino , Técnica del Anticuerpo Fluorescente , Humanos , Inmunohistoquímica , Contracción Muscular/fisiología , Relajación Muscular/fisiología , Músculo Liso , Óxido Nítrico Sintasa/metabolismo , Óxido Nítrico Sintasa de Tipo IRESUMEN
Phosphodiesterase type 5 (PDE5) inhibitors have reduced efficacy in treating erectile dysfunction (ED) in conditions where there is a lack of endogenous nitric oxide (NO). Therefore, NO-releasing PDE5 inhibitors have been developed. Here we report the effect of such a compound, NCX-911, on the tone and nitrergic relaxations of rabbit corpus cavernosum in the absence or presence of a NO synthase inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME; 500 microM). NCX-911 was found to be as potent as sildenafil at inducing relaxation of rabbit cavernosum (EC(50) values 997.8+/-195.7 and 1000.5+/-140.8 nM, respectively). The potency of NCX-911 was not altered, but that of sildenafil decreased five-fold in the presence of L-NAME (EC(50) values 1281.2+/-268.3 and 4959.1+/-882.1, nM respectively, P<0.001 for sildenafil). Both compounds potentiated nitrergic relaxations with similar potencies. These results suggest that NO-releasing PDE5 inhibitors could potentially be more useful than PDE5 inhibitors in the treatment of ED in conditions where there is a lack of endogenous NO.
Asunto(s)
Óxido Nítrico/metabolismo , Pene/efectos de los fármacos , Inhibidores de Fosfodiesterasa/farmacología , Hidrolasas Diéster Fosfóricas/efectos de los fármacos , Piperazinas/farmacología , Espermina/análogos & derivados , 3',5'-GMP Cíclico Fosfodiesterasas , Animales , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 5 , Disfunción Eréctil/tratamiento farmacológico , Técnicas In Vitro , Masculino , Relajación Muscular/efectos de los fármacos , NG-Nitroarginina Metil Éster/farmacología , Óxido Nítrico/farmacología , Donantes de Óxido Nítrico/farmacología , Óxido Nítrico Sintasa/antagonistas & inhibidores , Óxidos de Nitrógeno , Pene/fisiología , Fenilefrina/farmacología , Purinas , Conejos , Citrato de Sildenafil , Espermina/farmacología , Sulfonas , Vasoconstrictores/farmacologíaRESUMEN
Rho-kinase is an enzyme involved in the Ca2+-sensitizing pathway in smooth muscle cells. Inhibition of this enzyme has been recently demonstrated to elicit penile erection by relaxing cavernosal smooth muscle. We aimed to investigate the presence and activity of Rho-kinase in human cavernosal smooth muscle. Primary culture of smooth muscle cells from human and rabbit penile corpus cavernosum was developed, and cells showed characteristic myocyte morphology and alpha-actin immunoreactivity. The presence of Rho-kinase was demonstrated by indirect immunofluorescence and Western blotting. A specific inhibitor of Rho-kinase, Y-27632, inhibited in a concentration-dependent manner the kinase activity of the protein immunoprecipitated with anti-Rho-kinase antibody. These results demonstrate for the first time expression and activity of Rho-kinase in human penile cavernosal smooth muscle cells and suggest that these cells can provide a cellular model for the study of enzymes involved in Ca2+-sensitizing pathways.
Asunto(s)
Músculo Liso/enzimología , Pene/enzimología , Proteínas Serina-Treonina Quinasas/metabolismo , Actinas/metabolismo , Amidas/administración & dosificación , Amidas/farmacología , Animales , Western Blotting , Células Cultivadas , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/farmacología , Técnica del Anticuerpo Fluorescente Indirecta , Humanos , Péptidos y Proteínas de Señalización Intracelular , Masculino , Músculo Liso/metabolismo , Concentración Osmolar , Pene/citología , Pene/metabolismo , Pruebas de Precipitina , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Piridinas/administración & dosificación , Piridinas/farmacología , Conejos , Quinasas Asociadas a rhoRESUMEN
Erectile dysfunction (ED) is defined as the inability to achieve and maintain a penile erection adequate for satisfactory sexual intercourse. It is a significant male health problem of global dimensions affecting approximately 150 million men worldwide. A broad range of options are currently available for the management of ED. They include oral agents (phosphodiesterase 5 inhibitors, dopamine agonists and alpha-receptor blocking drugs), intracavernosal injection (papaverine, phentolamine, prostaglandin E1, vasoactive intestinal peptide), transurethral vasoactive agents (prostaglandin E1), vacuum erection devices, vascular surgery and penile prostheses. Here we review the physiology of penile erection and the currently available oral preparations. In addition, novel therapeutic strategies to improve erectile function are discussed.
Asunto(s)
Disfunción Eréctil/tratamiento farmacológico , 3',5'-GMP Cíclico Fosfodiesterasas/antagonistas & inhibidores , Administración Oral , Antagonistas Adrenérgicos alfa/uso terapéutico , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 5 , Agonistas de Dopamina/uso terapéutico , Disfunción Eréctil/fisiopatología , Guanilato Ciclasa , Humanos , Péptidos y Proteínas de Señalización Intracelular , Masculino , Pene/inervación , Pene/fisiopatología , Inhibidores de Fosfodiesterasa/uso terapéutico , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Receptores Citoplasmáticos y Nucleares/agonistas , Guanilil Ciclasa Soluble , Quinasas Asociadas a rhoRESUMEN
Erectile dysfunction (ED) due to diabetes mellitus remains difficult to treat medically despite advances in pharmacotherapeutic approaches in the field. This unmet need has resulted in a recent re-focus on the pathophysiology, in order to understand the cellular and molecular mechanisms leading to ED in diabetes. Diabetes-induced ED is often resistant to PDE5 inhibitor treatment, thus there is a need to discover targets that may lead to novel approaches for a successful treatment. The aim of this brief review is to update the reader in some of the latest development on that front, with a particular focus on the role of impaired neuronal blood flow and the formation of advanced glycation endproducts.
Asunto(s)
Neuropatías Diabéticas/fisiopatología , Disfunción Eréctil/fisiopatología , Productos Finales de Glicación Avanzada/metabolismo , Vasa Nervorum/fisiopatología , Neuropatías Diabéticas/metabolismo , Disfunción Eréctil/tratamiento farmacológico , Disfunción Eréctil/metabolismo , Humanos , Masculino , Inhibidores de Fosfodiesterasa 5/uso terapéutico , Vasa Nervorum/metabolismoRESUMEN
Although the putative 5-HT(1P) receptor has been implicated to have a role in peristalsis, experiments which suggest this function are preliminary or have measured only components of the reflex. We have, therefore, further characterized a reported agonist at this receptor (5-hydroxyindalpine; 5-OHIP) and investigated the effects of 5-OHIP and 5-hydroxytrytophan-dipeptide (5-HTP-DP), a reported 5-HT(1P) receptor antagonist, on distension-induced peristalsis in mouse colon. The effects of 5-OHIP on intracellular calcium, cyclic adenosine monophosphate concentrations or GTPgammaS binding were measured in cell lines expressing human recombinant 5-HT(1A, 1B, 1D, 2A, 2B, 2C, 3, 4, 6, 7) and alpha(1A), alpha(1B), D(1), D(2), D(3), H(1), H(3) receptors. The effects of 5-OHIP and 5-HTP-DP on peristalsis were assessed by measuring changes in frequency and times to reach threshold of peristaltic contractions, as well as the threshold and maximum pressures of each peristaltic stroke. 5-hydroxyindalpine (1 nmol L(-1)-10 micromol L(-1)) had no significant activity at any of the receptors studied. However, 5-OHIP (0.1 nmol L(-1)-1 micromol L(-1)) concentration-dependently increased the frequency of peristalsis (EC(50) = 4.4 nmol L(-1)) and reduced the time taken to reach threshold and threshold pressure, without altering maximum pressures. The maximum effect of 5-OHIP was at 1 micromol L(-1) (68.0 +/- 14.5% increase in frequency); 10 micromol L(-1) decreased peristalsis. 5-hydroxytrytophan-dipeptide (1-300 nmol L(-1)) also increased the frequency of peristalsis and prevented the actions of 5-OHIP. The higher concentration (1 micromol L(-1)) transiently inhibited peristalsis and after recovery, prevented the actions of 5-OHIP but not the excitatory activity of the cholinesterase inhibitor neostigmine. In summary, the present data demonstrate an interaction of '5-HT(1P)-ligands' with the peristaltic reflex. However, the absence of an effect of 5-OHIP on a range of different monoamine receptors continues to highlight the need to investigate the identity of the putative 5-HT(1P) receptor.
Asunto(s)
Peristaltismo/efectos de los fármacos , Piperidinas/farmacología , Receptores de Serotonina/metabolismo , Agonistas de Receptores de Serotonina/farmacología , Animales , Colon/efectos de los fármacos , Colon/fisiología , Humanos , Masculino , Manometría , Ratones , Técnicas de Cultivo de Órganos , Peristaltismo/fisiología , Receptores de Serotonina/efectos de los fármacos , Proteínas Recombinantes/efectos de los fármacos , Proteínas Recombinantes/metabolismo , TransfecciónRESUMEN
There is an urgent clinical need for a safe, efficacious stimulant of gastric emptying; current therapies include erythromycin (an antibiotic with additional properties which preclude chronic use) and metoclopramide (a 5-hydroxytryptamine type 4 receptor agonist and an antagonist at brain D2 receptors, associated with movement disorders). To move away from the complex motilide structure of erythromycin, a small molecule motilin receptor agonist, GSK962040, was identified and characterized. The compound was evaluated using recombinant human receptors, rabbit and human isolated stomach preparations known to respond to motilin and in vivo, by measuring its ability to increase defecation in conscious rabbits. At the human motilin receptor, the pEC50 (the negative logarithm to base 10 of the EC50 value, the concentration of agonist that produces 50% of the maximal response) values for GSK962040 and erythromycin as agonists were, respectively, 7.9 and 7.3; GSK962040 had no significant activity at a range of other receptors (including ghrelin), ion channels and enzymes. In rabbit gastric antrum, GSK962040 300 nmol L(-1)-10 micromol L(-1) caused a prolonged facilitation of the amplitude of cholinergically mediated contractions, to a maximum of 248 +/- 47% at 3 micromol L(-1). In human-isolated stomach, GSK962040 10 micromol L(-1), erythromycin 10 micromol L(-1) and [Nle13]-motilin 100 nmol L(-1), each caused muscle contraction of similar amplitude. In conscious rabbits, intravenous doses of 5 mg kg(-1) GSK962040 or 10 mg kg(-1) erythromycin significantly increased faecal output over a 2-h period. Together, these data show that GSK962040, a non-motilide structure, selectively activates the motilin receptor. Simplification of the structural requirements to activate this receptor greatly facilitates the design of potentially new medicines for gastroparesis.